Neither NBN gain nor NBN mRNA expression (or expression of its partner, KPNA2) was prognostic in the surgery cohort; consistent with previous publications on Nibrin expression in surgically treated prostate cancer patients [15-16]. The gene discussed is KPNA2; the disease is prostate carcinoma.